The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »Can Muscle Quality Predict Diabetes Outcomes Better Than BMI?
For decades, body mass index (BMI) has been the standard tool for assessing metabolic health and diabetes risk. However, many clinicians now question whether weight alone tells the full story. Some people with a “normal” BMI still develop insulin resistance and type 2 diabetes, while others with higher body weight …
Read More »GLP-1 Therapy and Muscle Loss: Are We Overlooking Sarcopenia Risk?
Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.